Get the Stockscreener App
3.355
1.13%
-0.065
Third Harmonic Bio Inc stock is traded at $3.355, with a volume of 295.73K.
It is down -1.13% in the last 24 hours and down -36.08% over the past month.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.
See More
Previous Close:
$3.42
Open:
$3.41
24h Volume:
295.73K
Relative Volume:
0.54
Market Cap:
$154.10M
Revenue:
-
Net Income/Loss:
$-32.74M
P/E Ratio:
-4.0915
EPS:
-0.82
Net Cash Flow:
$-24.89M
1W Performance:
-2.56%
1M Performance:
-36.08%
6M Performance:
-71.42%
1Y Performance:
-66.95%
1-Day Range:
$3.36
$3.48
1-Week Range:
$3.36
$3.56
52-Week Range:
$3.18
$16.94
Third Harmonic Bio Inc Stock (THRD) Company Profile
Name
Third Harmonic Bio Inc
Sector
Industry
Phone
(209) 727-2457
Address
1700 MONTGOMERY STREET, SAN FRANCISCO
Compare THRD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
THRD
Third Harmonic Bio Inc
|
3.36 | 154.10M | 0 | -32.74M | -24.89M | -0.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
475.24 | 121.85B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
695.97 | 76.83B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
616.76 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.50 | 30.69B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
268.06 | 29.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Third Harmonic Bio Inc Stock (THRD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-11-25 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Aug-09-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-18-24 | Initiated | Stifel | Buy |
| Jun-07-24 | Initiated | Raymond James | Outperform |
| Dec-16-22 | Downgrade | Jefferies | Buy → Hold |
| Dec-15-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-10-22 | Initiated | Cowen | Outperform |
| Oct-10-22 | Initiated | Jefferies | Buy |
| Oct-10-22 | Initiated | Morgan Stanley | Overweight |
View All
Third Harmonic Bio Inc Stock (THRD) Latest News
Layoff Tracker: Lava, Ryvu Cutting 30% of Their Workforces - BioSpace
Companies Like Third Harmonic Bio (NASDAQ:THRD) Are In A Position To Invest In Growth - Yahoo Finance
Third Harmonic Bio downgraded to Market Perform from Outperform at Raymond James - MSN
Third Harmonic Bio progresses THB335 to Phase 2 trial - MSN
Third Harmonic Bio, Inc. (THRD) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Down -39.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Third Harmonic Bio, Inc. (THRD) - Nasdaq
Third Harmonic stock rating cut by Raymond James - MSN
Third Harmonic Bio Initiates Strategic Review, Lays Off 50% Staff Citing Competitive Landscape - AOL
Raymond James downgrades Third Harmonic Bio on uncertainty for only asset - MSN
Morgan Stanley Downgrades Third Harmonic Bio to Equalweight From Overweight, Cuts Price Target to $5 From $20 - Marketscreener.com
Third Harmonic and Inventiva slash workforces - The Pharma Letter
Third Harmonic Bio progresses THB335 to Phase 2 trial By Investing.com - Investing.com Nigeria
Morgan Stanley cuts Third Harmonic stock rating amid uncertainty - MSN
Finance Watch: Third Harmonic, Q32 Bio Cut Jobs To Focus On Lead Assets - News & Insights
Morgan Stanley cuts Third Harmonic stock rating amid uncertainty By Investing.com - Investing.com Canada
Third Harmonic Bio, Inc.: Hold Rating Amid Strategic Uncertainty and Safety Concerns - TipRanks
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Optimistic Buy Rating for Third Harmonic Bio Amid Promising Trial Results and Safety Concerns - TipRanks
Third Harmonic Bio Inc (THRD) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Stock market news: Fluence Energy -47.86%, Columbus McKinnon -40.83% among biggest losers during midday trading - Business Upturn
Third Harmonic stock rating cut by Raymond James By Investing.com - Investing.com South Africa
Merck KGaA pursuing Springworks; BridgeBio wins EU drug OK - BioPharma Dive
Third Harmonic Bio Shares Slump After 50% Workforce Cut, Strategic Review Set -February 11, 2025 at 10:34 am EST - Marketscreener.com
Stock market today: Fluence Energy -46.44%, Columbus McKinnon -42.05% among biggest losers in early trading - Business Upturn
Third Harmonic Bio, Inc. Announces Restructuring Plan - TipRanks
Third Harmonic Bio stock tumbles after clinical trial results - Investing.com
Hain Celestial Group Inc’s Mixed Bag: Down -43.22% in 6 Months, Down -22.12% in 30 Days - The InvestChronicle
Third Harmonic Bio stock tumbles after clinical trial results By Investing.com - Investing.com South Africa
Third Harmonic halves headcount to take urticaria drug into phase 2 despite side effects - Fierce Biotech
Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 and Provides Corporate Strategic Update - The Manila Times
Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 and Provides Corporate - The Bakersfield Californian
Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 -February 11, 2025 at 07:00 am EST - Marketscreener.com
(THRD) Investment Analysis - Stock Traders Daily
Spruce Biosciences Inc (NASDAQ: SPRB) Stock Has Gained 4.05% Over The Month – Is There Room For Growth? - Marketing Sentinel
Should You Expect Akero Therapeutics Inc (NASDAQ:AKRO) To Recover From Its 70.02% Gain From Highs? - Marketing Sentinel
Five Point Holdings LLC (NYSE: FPH): Can The Stock Still Lose Despite An 54.23% YTD Gain? - Marketing Sentinel
After Falling -7.79% During The Past Week, Should You Still Buy Third Harmonic Bio Inc (NASDAQ: THRD)? - Marketing Sentinel
Analytical Overview: Orasure Technologies Inc (OSUR)’s Ratios Tell a Financial Story - The Dwinnex
Balance Sheet Insights: Chart Industries Inc (GTLS)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Ratios Reveal: Breaking Down Third Harmonic Bio Inc (THRD)’s Financial Health - The Dwinnex
THRD: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle
Third Harmonic Bio Inc Stock (THRD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Third Harmonic Bio Inc Stock (THRD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Conner Edward R. | Chief Medical Officer |
Nov 08 '24 |
Sale |
15.00 |
2,117 |
31,755 |
0 |
| BVF PARTNERS L P/IL | See Explanation of Responses |
Oct 29 '24 |
Sale |
14.30 |
1,000,000 |
14,300,000 |
176,692 |
| Conner Edward R. | Chief Medical Officer |
Oct 28 '24 |
Option Exercise |
4.20 |
2,673 |
11,227 |
2,673 |
| Conner Edward R. | Chief Medical Officer |
Oct 28 '24 |
Sale |
15.00 |
2,673 |
40,095 |
0 |
1.44%
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):